Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga/177Lu-BRP-020063 in Advanced Metastatic Solid Tumors
NCT07439120Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Primary completion
- Aug 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga/177Lu-BRP-020063 in solid tumor, urothelial carcinoma (UC) and breast cancer, sponsored by Shanghai General Hospital. Primary endpoint: Adverse Events at 4 weeks. Started Apr 2026; status: recruiting.
02
Drugs
68Ga/177Lu-BRP-020063
03
Conditions
solid tumorurothelial carcinoma (UC)breast cancer
Beyond the preview
Go deeper on NCT07439120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439120.